FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000749502> ?p ?o ?g. }

• W3000749502 endingPage "S72" @default.
• W3000749502 startingPage "S71" @default.
• W3000749502 abstract "There are reports of high rates of viral infections after haploidentical transplant, particularly in the setting of PTCy (HaploCy) but detailed data on incidence are lacking. We describe here the comparative incidence of community respiratory virus (CRV) infections occurring by day 180 post-transplant by donor source and their impact on outcomes including survival, relapse, chronic GVHD, and transplant related mortality (TRM) using CIBMTR registry data. The analysis included 2765 patients, all > 2 years of age, who underwent first allogeneic HCT for AML, ALL or MDS from 100 centers between 2012 and 2017 receiving either HaploCy (n=757), Matched related donor (MRD) transplant with PTCy (SibCy n= 403), and MRD transplant with calcineurin inhibitor and either MTX or MMF (SibCNI n= 1605).The cumulative incidences of CRV in the HaploCy, SibCy and SibCNI were: 3% (99% CI, 1.6-4.8), 3% (1.3-5.5) and 2.4 %(1.5-3.5) respectively at day 30 (P =0.649, NS), but notably higher at 15.5% (12.3-19), 16.2% (11.7-21.2) and 9.4 %(7.6-11.4) at 6 months (P<.001) post-transplant [Figure 1]. Identified CRV included primarily Rhinovirus, Parainfluenza, and RSV accounting for approximately 70% of all CRV reported [Table 1]. Figure 2 shows the multivariable models through 2 years post-transplant for survival, relapse, TRM, and chronic GVHD with a reference group of SibCNI without CRV infection for the main effect variable of donor type and infection. Patients in the HaploCy cohort who developed a CRV by day 180 had a higher risk of TRM [p=0.002] and inferior survival [p = 0.001] compared to the reference group. Older age, more advanced disease, and higher HCT-CI were all associated with increased mortality.The incidence of CRVs is higher for patients receiving PTCy, regardless of donor. This finding justifies further studies to understand long-term antiviral immune recovery in different donor sources and GVHD prophylaxis regimens. The higher overall mortality for HaploCy patients developing CRV infection warrants consideration for patient education and heightened awareness for clinicians, as well as long term follow up studies of such patients. There are reports of high rates of viral infections after haploidentical transplant, particularly in the setting of PTCy (HaploCy) but detailed data on incidence are lacking. We describe here the comparative incidence of community respiratory virus (CRV) infections occurring by day 180 post-transplant by donor source and their impact on outcomes including survival, relapse, chronic GVHD, and transplant related mortality (TRM) using CIBMTR registry data. The analysis included 2765 patients, all > 2 years of age, who underwent first allogeneic HCT for AML, ALL or MDS from 100 centers between 2012 and 2017 receiving either HaploCy (n=757), Matched related donor (MRD) transplant with PTCy (SibCy n= 403), and MRD transplant with calcineurin inhibitor and either MTX or MMF (SibCNI n= 1605). The cumulative incidences of CRV in the HaploCy, SibCy and SibCNI were: 3% (99% CI, 1.6-4.8), 3% (1.3-5.5) and 2.4 %(1.5-3.5) respectively at day 30 (P =0.649, NS), but notably higher at 15.5% (12.3-19), 16.2% (11.7-21.2) and 9.4 %(7.6-11.4) at 6 months (P<.001) post-transplant [Figure 1]. Identified CRV included primarily Rhinovirus, Parainfluenza, and RSV accounting for approximately 70% of all CRV reported [Table 1]. Figure 2 shows the multivariable models through 2 years post-transplant for survival, relapse, TRM, and chronic GVHD with a reference group of SibCNI without CRV infection for the main effect variable of donor type and infection. Patients in the HaploCy cohort who developed a CRV by day 180 had a higher risk of TRM [p=0.002] and inferior survival [p = 0.001] compared to the reference group. Older age, more advanced disease, and higher HCT-CI were all associated with increased mortality. The incidence of CRVs is higher for patients receiving PTCy, regardless of donor. This finding justifies further studies to understand long-term antiviral immune recovery in different donor sources and GVHD prophylaxis regimens. The higher overall mortality for HaploCy patients developing CRV infection warrants consideration for patient education and heightened awareness for clinicians, as well as long term follow up studies of such patients. Figures 1, 2 and Table 1.Figure 2Multivariable models for transplant outcomes.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Table 1Identified CRV by Transplant Type.HaploCy N = 757 (%)SibCy N= 403 (%)SibCNI N=1605 (%)Rhinovirus27 (4)30 (7)53 (3)Parainfluenza24 (3)15 (4)41 (3)RSV32 (4)10 (2)45 (2)Influenza16 (2)8 (2)24 (1)Adenovirus20 (3)12 (3)15 (1)Enterovirus6 (1)5 (1)7 (<1)Human metapneumovirus2 (<1)04 (<1)Coronavirus3 (<1)03 (<1) Open table in a new tab" @default.
• W3000749502 created "2020-01-30" @default.
• W3000749502 creator A5002455488 @default.
• W3000749502 creator A5004885286 @default.
• W3000749502 creator A5008162182 @default.
• W3000749502 creator A5008376636 @default.
• W3000749502 creator A5012718640 @default.
• W3000749502 creator A5034219527 @default.
• W3000749502 creator A5036228481 @default.
• W3000749502 creator A5041206856 @default.
• W3000749502 creator A5057832944 @default.
• W3000749502 creator A5061484901 @default.
• W3000749502 creator A5065373363 @default.
• W3000749502 creator A5065590894 @default.
• W3000749502 creator A5070794158 @default.
• W3000749502 creator A5074706721 @default.
• W3000749502 creator A5082092102 @default.
• W3000749502 creator A5091083304 @default.
• W3000749502 date "2020-03-01" @default.
• W3000749502 modified "2023-10-09" @default.
• W3000749502 title "Incidence and Impact of Community Respiratory Viral Infection (CRV) in Haploidentical and Matched Sibling Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis" @default.
• W3000749502 doi "https://doi.org/10.1016/j.bbmt.2019.12.219" @default.
• W3000749502 hasPublicationYear "2020" @default.
• W3000749502 type Work @default.
• W3000749502 sameAs 3000749502 @default.
• W3000749502 citedByCount "0" @default.
• W3000749502 crossrefType "journal-article" @default.
• W3000749502 hasAuthorship W3000749502A5002455488 @default.
• W3000749502 hasAuthorship W3000749502A5004885286 @default.
• W3000749502 hasAuthorship W3000749502A5008162182 @default.
• W3000749502 hasAuthorship W3000749502A5008376636 @default.
• W3000749502 hasAuthorship W3000749502A5012718640 @default.
• W3000749502 hasAuthorship W3000749502A5034219527 @default.
• W3000749502 hasAuthorship W3000749502A5036228481 @default.
• W3000749502 hasAuthorship W3000749502A5041206856 @default.
• W3000749502 hasAuthorship W3000749502A5057832944 @default.
• W3000749502 hasAuthorship W3000749502A5061484901 @default.
• W3000749502 hasAuthorship W3000749502A5065373363 @default.
• W3000749502 hasAuthorship W3000749502A5065590894 @default.
• W3000749502 hasAuthorship W3000749502A5070794158 @default.
• W3000749502 hasAuthorship W3000749502A5074706721 @default.
• W3000749502 hasAuthorship W3000749502A5082092102 @default.
• W3000749502 hasAuthorship W3000749502A5091083304 @default.
• W3000749502 hasBestOaLocation W30007495021 @default.
• W3000749502 hasConcept C120665830 @default.
• W3000749502 hasConcept C121332964 @default.
• W3000749502 hasConcept C126322002 @default.
• W3000749502 hasConcept C128057223 @default.
• W3000749502 hasConcept C2776694085 @default.
• W3000749502 hasConcept C2776755627 @default.
• W3000749502 hasConcept C2780611847 @default.
• W3000749502 hasConcept C2911091166 @default.
• W3000749502 hasConcept C61511704 @default.
• W3000749502 hasConcept C71924100 @default.
• W3000749502 hasConcept C72563966 @default.
• W3000749502 hasConcept C88879693 @default.
• W3000749502 hasConceptScore W3000749502C120665830 @default.
• W3000749502 hasConceptScore W3000749502C121332964 @default.
• W3000749502 hasConceptScore W3000749502C126322002 @default.
• W3000749502 hasConceptScore W3000749502C128057223 @default.
• W3000749502 hasConceptScore W3000749502C2776694085 @default.
• W3000749502 hasConceptScore W3000749502C2776755627 @default.
• W3000749502 hasConceptScore W3000749502C2780611847 @default.
• W3000749502 hasConceptScore W3000749502C2911091166 @default.
• W3000749502 hasConceptScore W3000749502C61511704 @default.
• W3000749502 hasConceptScore W3000749502C71924100 @default.
• W3000749502 hasConceptScore W3000749502C72563966 @default.
• W3000749502 hasConceptScore W3000749502C88879693 @default.
• W3000749502 hasIssue "3" @default.
• W3000749502 hasLocation W30007495021 @default.
• W3000749502 hasLocation W30007495022 @default.
• W3000749502 hasOpenAccess W3000749502 @default.
• W3000749502 hasPrimaryLocation W30007495021 @default.
• W3000749502 hasRelatedWork W1978820438 @default.
• W3000749502 hasRelatedWork W1984535202 @default.
• W3000749502 hasRelatedWork W2084783894 @default.
• W3000749502 hasRelatedWork W2435305444 @default.
• W3000749502 hasRelatedWork W2805955160 @default.
• W3000749502 hasRelatedWork W2905168405 @default.
• W3000749502 hasRelatedWork W4310641312 @default.
• W3000749502 hasRelatedWork W4321616443 @default.
• W3000749502 hasRelatedWork W4386423326 @default.
• W3000749502 hasRelatedWork W2464485693 @default.
• W3000749502 hasVolume "26" @default.
• W3000749502 isParatext "false" @default.
• W3000749502 isRetracted "false" @default.
• W3000749502 magId "3000749502" @default.
• W3000749502 workType "article" @default.